- Home
- NML vs AQST Comparison
NML vs AQST Comparison
Compare NML & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NML
- AQST
- Stock Information
- Founded
- NML 2012
- AQST 2004
- Country
- NML United States
- AQST United States
- Employees
- NML N/A
- AQST N/A
- Industry
- NML Finance/Investors Services
- AQST Biotechnology: Pharmaceutical Preparations
- Sector
- NML Finance
- AQST Health Care
- Exchange
- NML Nasdaq
- AQST Nasdaq
- Market Cap
- NML 461.2M
- AQST 502.6M
- IPO Year
- NML N/A
- AQST 2018
- Fundamental
- Price
- NML $8.41
- AQST $3.65
- Analyst Decision
- NML
- AQST Strong Buy
- Analyst Count
- NML 0
- AQST 8
- Target Price
- NML N/A
- AQST $10.38
- AVG Volume (30 Days)
- NML 219.3K
- AQST 1.7M
- Earning Date
- NML 01-01-0001
- AQST 11-04-2024
- Dividend Yield
- NML 9.75%
- AQST N/A
- EPS Growth
- NML N/A
- AQST N/A
- EPS
- NML N/A
- AQST N/A
- Revenue
- NML N/A
- AQST $58,900,000.00
- Revenue This Year
- NML N/A
- AQST $18.45
- Revenue Next Year
- NML N/A
- AQST N/A
- P/E Ratio
- NML N/A
- AQST N/A
- Revenue Growth
- NML N/A
- AQST 22.56
- 52 Week Low
- NML $6.09
- AQST $1.86
- 52 Week High
- NML $7.33
- AQST $6.23
- Technical
- Relative Strength Index (RSI)
- NML 34.98
- AQST 36.47
- Support Level
- NML $8.92
- AQST $3.38
- Resistance Level
- NML $8.59
- AQST $3.92
- Average True Range (ATR)
- NML 0.21
- AQST 0.24
- MACD
- NML -0.12
- AQST -0.04
- Stochastic Oscillator
- NML 17.50
- AQST 19.01
About NML Neuberger Berman Energy Infrastructure and Income Fund Inc.
Neuberger Berman Energy Infrastructure & Income Fund Inc is a closed-end investment management company based in the United States.
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Sympazan Oral Film, Suboxone Sublingual Film, Exservan Oral Film, and Zuplenz. The product pipeline includes Libervant Buccal Film, AQST-108, and AQST-305. The majority of its revenue comes from the United States.